Company news
Starpharma Holdings Limited news in 2016
Starpharma Holdings Limited's news releases, calls and decks from 2016, newest first.
SPL: VivaGel condom approved for sale with launch imminent
March 30, 2016
DEP docetaxel - longer duration and increased exposure
March 30, 2016
Adama Licenses Starpharmas Priostar for Novel 2,4-D
March 16, 2016
Starpharma licences VivaGel BV to Aspen for ANZ
March 3, 2016
Targeted DEP shows sustained superior performance
February 11, 2016
VivaGel phase 3 study results
February 10, 2016
VivaGel Demonstrates Efficacy in Bacterial Vaginosis
February 10, 2016
VivaGel condom patent grant extends coverage
February 10, 2016
VivaGel Coated Condom Licence Agreement with Okamoto Japan
February 10, 2016
VivaGel BV Phase 3 trials - recruitment complete
February 10, 2016
Starpharma to recoup additional $2 million for overseas R&D
February 10, 2016
Starpharmas Priostar Glyphosate Patent Allowed in China
February 10, 2016
Starpharma signs MOU for VivaGel condom in China
February 10, 2016
Starpharma`s drug delivery program with Lilly advances
February 10, 2016
Starpharmas docetaxel demonstrates targeted tumour delivery
February 10, 2016
Starpharma receives $3.4M R&D tax incentive
February 10, 2016
Starpharma raises $1.9M under Share Purchase Plan
February 10, 2016
Starpharma Granted New Drug Delivery Patents
February 10, 2016
Starpharma expands Drug Delivery Program with AstraZeneca
February 10, 2016
Starpharma completes A$32 million placement, SPP to follow
February 10, 2016
Starpharma completes A$32 million placement
February 10, 2016
Starpharma announces Phase 2 BV study of VivaGel
February 10, 2016
Starpharma and Nufarm sign crop protection agreement
February 10, 2016
Starpharma advances agrochemical program
February 10, 2016
SPL to expand agricultural program through $250,000 funding
February 10, 2016
SPL: Marketing Clearance for VivaGel condom in New Zealand
February 10, 2016
SPL and Monash University collaboration receives ARC grant
February 10, 2016
Response to ASX Query
February 10, 2016
Response to ASX Price Query
February 10, 2016
New formulations show further improvement in crop protection
February 10, 2016
Japan VivaGel condom classification impacts launch timing
February 10, 2016
Full enrolment achieved for BV Phase 2 & first Phase 3 trial
February 10, 2016
EU Marketing Approval Granted for VivaGel BV
February 10, 2016
DEP outperforms leading treatments in ovarian cancer model
February 10, 2016
DEP Docetaxel Trial Dose Exceeds Common Taxotere Dose Level
February 10, 2016
Dendrimer-Oxaliplatin shows better anti-cancer efficacy
February 10, 2016
Completes enrolment for Phase 2 study of VivaGel for BV
February 10, 2016
Cancer Australia funding for dendrimer-based lung treatment
February 10, 2016
Appendix 4C - quarterly
February 10, 2016
Annual Report and full year financial results
February 10, 2016
Additional US Patent Granted for VivaGel BV
February 10, 2016
Decks in 2016
- Shareholder Meeting (November 2016)
Shareholder meeting · 45 slides · Nov 29, 2016
- FY2016 Earnings Presentation
Earnings · 12 slides · Aug 30, 2016